Zenas BioPharma (ZBIO) Interest Expenses (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Interest Expenses of $68.9 million for Q1 2026, up 3570.32% year-over-year from $1.9 million in Q1 2025, and down 71.76% quarter-over-quarter from $244.0 million in Q4 2025.
Zenas BioPharma (ZBIO) Interest Expenses (2023 - 2026) Analysis & Trends
Zenas BioPharma's Interest Expenses history runs 4 years deep, the most recent figure standing at $68.9 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 3570.32% year-over-year to $68.9 million; the TTM figure through Mar 2026 stood at $68.9 million (up 3570.32% YoY), while the FY2025 annual figure was $244.0 million, up 170.2% from the prior year.
- Interest Expenses for Q1 2026 stood at $68.9 million, down from $244.0 million in the prior quarter.
- The five-year high for Interest Expenses was $258.0 million in Q3 2024, with the low at $550000.0 in Q4 2023.
- The 4-year median for Interest Expenses is $36.2 million (2025), against an average of $84.6 million.
- Peak annual rise in Interest Expenses reached 11495.96% in 2025, while the deepest fall reached 61.96% in 2025.
- Zenas BioPharma's Interest Expenses stood at $550000.0 in 2023, then surged by 282.55% to $2.1 million in 2024, then surged by 11495.96% to $244.0 million in 2025, then plunged by 71.76% to $68.9 million in 2026.
- Business Quant data shows ZBIO's Interest Expenses at $68.9 million in Q1 2026, $244.0 million in Q4 2025, and $98.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 139.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 139.39 Mn |
| Jun 30, 2026 | 139.39 Mn |
| Mar 31, 2026 | 68.89 Mn |
| Mar 31, 2026 | 68.89 Mn |
| Dec 31, 2025 | 243.98 Mn |
| Dec 31, 2025 | 243.98 Mn |
| Sep 30, 2025 | 98.13 Mn |
| Sep 30, 2025 | 98.13 Mn |
| Jun 30, 2025 | 3.51 Mn |
| Jun 30, 2025 | 3.51 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 258.00 Mn |
| Sep 30, 2024 | 258.00 Mn |
| Dec 31, 2023 | 550,000.00 |
| Dec 31, 2023 | 550,000.00 |